澳门赌场招聘-赌场有哪些_免费百家乐追号软件_全讯网最新资讯网址 (中国)·官方网站

Research News

Nature Reviews Drug Discovery: targeting cancer-associated fibroblasts

Share
  • Updated: Dec 24, 2018
  • Written:
  • Edited:
Source: Sun Yat-sen Memorial Hospital
Written by: Xueman Chen
Edited by: Wang Dongmei

Recently, a Review Article entitled “Turning foes to friends: targeting cancer-associated fibroblasts” was published online in Nature Reviews Drug Discovery (IF 2018=50.17)1. Professor Erwei Song, President of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, is the corresponding author, and Xueman Chen, a PhD student from his team, is the first author.

Current paradigms of cancer-centric therapeutics are usually not sufficient to eradicate the malignancy, as the cancer stroma may prompt tumor relapse and therapeutic resistance. In the past decade, a burst of knowledge on how the tumor microenvironment (TME) interacts with tumor cells has urged studies on a new cancer treatment paradigm: targeting the tumor stroma. Among all the stromal cells that populate the TME, cancer-associated fibroblasts (CAFs) are the most abundant and are critically involved in cancer progression, which render them as conspicuous stromal targets in many, if not all, solid tumors. However, without unequivocal cell-surface markers, live-cell sorting for functional and mechanistic studies on CAFs in vitro and targeting therapies towards CAFs in vivo are greatly hindered.

It is noteworthy that a previous research from Prof. Erwei Song’s team revealed CD10 and GPR77 as two specific cell-surface makers for a novel pro-tumorigenic CAF subset involved in cancer stemness and chemoresistance2. More importantly, GPR77 is a functional marker which can be directly targeted for in vivo CAF depletion. The restoration of chemosensitivity of tumor cells upon GPR77 blockade further suggests the remarkable therapeutic value of such a precise CAF-targeted strategy for cancers.


Accumulated molecular characterization of CAFs not only deepens our insights into their phenotypic heterogeneity and functional diversity, but also brings CAF-targeting therapies for cancer treatment onto the agenda. However, translating the basic research into clinical practice takes tremendous efforts and is extremely time-consuming, which makes it an urgent need for therapists and drug developers to comprehensively recognize the functional significance and molecular mechanisms of CAFs in cancers.

In this Review, Prof. Song’s team presented a full-scale overview regarding the current understanding of the hallmarks, biology and heterogeneity of CAFs, highlighting the CAF-centered intercellular crosstalk within the TME, and discussed multipronged functions of CAFs in tumor initiation, progression, metastasis and resistance to anticancer therapies. Prof. Song’s team also elaborated on the potential therapeutic strategies targeting CAFs, with an aim to accelerate the leap from bench to bedside.


References
1.  Chen, X. & Song, E. Turning foes to friends: targeting cancer-associated fibroblasts. Nature Reviews Drug Discovery (2018).
2.  Su, S., et al. CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell (2018).

Link to the review article: www.nature.com/articles/s41573-018-0004-1
TOP
百家乐官网tt娱乐| 明升国际娱乐 | 温州百家乐官网真人网| 利记娱乐| 百家乐棋牌交友| 澳门百家乐如何算牌| 百家乐路纸发表区| 金沙百家乐现金网| 菲律宾百家乐太阳城| 怎样玩百家乐看路| 博彩百家乐官网龙虎| 百家乐官网游戏机出千| 百家乐官网好多假网站| 百家乐官网棋牌辅助| 百家乐官网开户送8彩金| 大发888官方网址| 百家乐视频世界| 百家乐微心打法| 温州市百家乐鞋业| 全讯网321| 皇冠投注網| 色达县| A8百家乐官网现金网| 百家乐官网5式直缆投注法| 赤城县| 大发888在线投注| 皇冠网上投注网| 澳门百家乐官网门路| 百家乐官网对保| 百家乐技巧娱乐博彩| 马德里百家乐的玩法技巧和规则| 大发888娱乐场下载远程| 化州市| 百家乐官网街机| 聚众玩百家乐官网的玩法技巧和规则 | 请问下百家乐去哪个娱乐城玩最好呢 | 大发888集团| 易盈国际娱乐城| 百家乐官网黄金城游戏大厅| 百家乐官网永利娱乐场| 百家乐翻天youtube|